IPN60130

IPN60130

FOP is caused by a mutation in the ACVR1 gene that results in excessive bone morphogenetic protein (BMP) signaling, which regulates cartilage and bone development. The FOP mutation increases BMP signaling, resulting in the formation of heterotopic bone. IPN60130 is an oral investigational drug designed to selectively target the mutant FOP receptor (ACVR1/ALK2), the underlying cause of FOP. FDA has granted Fast Track Designation to IPN60130 for the treatment of FOP.

About the Clinical Trial

Ipsen conducted a

Phase 1
Phase 1: Studies in humans that assess safety and toxicity of a treatment in a small group of healthy volunteers or patients with the disease of interest.  

trial with IPN60130 in healthy volunteers (e.g. people without FOP) to establish the safety of the investigational drug.

Eligibility Criteria Icon
Eligibility Criteria*
  • AGE: ≥ 18
  • DISEASE ACTIVITY: Healthy volunteers only
  • MUTATIONS: n/a
Study Design Icon
Study Design*
  • STUDY TYPE:  Interventional
  • RANDOMIZED STUDY:  Yes
  • PLACEBO CONTROLLED:  Yes
  • LENGTH OF PARTICIPATION: n/a
  • NUMBER OF STUDY VISITS: n/a
Status Icon
Status

Completed

Therapy Approach Icon
Therapy Approach

Kinase Inhibitor

Study Sponsor Icon
Study Sponsor

Ipsen

 

The IFOPA does not endorse nor recommend specific clinical trials. Please speak with your doctor if you are interested in participating in a clinical trial.

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter